NEOGENOMICS INC 8-K

What Happened
NeoGenomics, Inc. (NEO) announced in an 8-K that its Board increased from nine to ten directors and appointed Carolyn S. Starrett as an independent director, effective June 23, 2026. Ms. Starrett will serve until the Company’s 2027 annual meeting of stockholders (and until her successor is elected or she resigns/removed). Her compensation will follow the Company’s existing director compensation program as disclosed in the 2026 proxy statement. The filing also includes a press release dated June 25, 2026, as Exhibit 99.1 under Regulation FD.

Key Details

• Board size increased from nine to ten directors; appointment effective June 23, 2026.
• Appointee: Carolyn S. Starrett; term ends at the 2027 annual meeting (or earlier upon resignation/removal).
• Director compensation will follow NeoGenomics’ previously disclosed 2026 proxy director compensation program.
• Press release announcing the appointment attached as Exhibit 99.1 to the 8-K (dated June 25, 2026).

Why It Matters
A new independent director alters board composition and can affect governance and oversight of management—important for shareholders monitoring board refreshment and corporate governance. The filing does not report changes to executive officers, financial results, or compensation details beyond the statement that Ms. Starrett will be paid per the existing director program. The attached press release provides NeoGenomics’ public disclosure of the appointment.